Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $9.39 Million |
|---|---|
| Enterprise Value | $69.35 Million |
| Earnings per Share | $-0.42 |
| Beta | 1.28 |
| Outstanding Shares | 42,694,000 |
| P/E Ratio | -0.38 |
|---|---|
| PEG | -0.25 |
| Price to Sales | - |
| Price to Book Ratio | -0.11 |
| Enterprise Value to Revenue | 4.84 |
| Enterprise Value to EBIT | -4.71 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.89 |
| Debt to Equity | -1.01 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Im...